UBS raises GitLab stock price target to $50 on revenue growth

UBS raised its GitLab (GTLB) price target to $50 from $40 while keeping a Neutral rating after Q2 FY2027 revenue of $286M (+21.3% YoY) beat expectations (~+4.5% vs high end of guidance). The firm flagged 87% gross margins and expects Q3 growth of ~21%, implying another likely beat, supported by emerging traction in non-developer seat additions (one telco adding 500–1,000 seats). Despite the positive results and multiple analyst target increases, UBS noted investor positioning remains bearish and shares trade at just over 5x calendar 2027 revenue, keeping the risk-reward balanced.

Analysis

This is less a re-rating setup than a durability check. The market already assigns a compressed multiple to a still-healthy grower, so the stock only keeps working if growth re-accelerates or if enterprise seat expansion proves durable enough to extend the runway beyond the core developer audience. The non-developer seat angle matters because it lifts TAM with minimal incremental software COGS, but it also pushes GitLab into a broader workflow battle where buying committees are larger and vendor consolidation can slow conversions.

Second-order, the real winners are enterprise customers that can standardize on one platform across engineering and business functions; that can pressure point solutions and smaller DevOps tools that lack suite breadth. The risk is that this expansion is not a new monetization engine but a re-labeling of existing account penetration, which would leave revenue growth steady but not accelerating and could eventually cap multiple expansion. If customer success and compliance effort rise faster than seat expansion, gross margin quality can quietly deteriorate even if headline margins stay high.

Near term, bearish positioning creates squeeze potential, but the catalyst path looks more like a tradable pop than a new trend unless the next print shows growth above the low-20s and better billings/NRR. The contrarian miss is that the market may be underestimating how much of the good news is already in the tape after the recent run, while overestimating the odds of a step-change in growth. Falsifiers are simple: a guide that fails to improve, sustained growth below 20%, or any evidence that non-dev seat adds are too small to move the revenue needle.

Key Decisions for Investors

• Tactical: fade strength in GTLB on any analyst-driven gap-up; expect 1-3 month upside to be capped unless management raises growth guidance. Use a tight risk budget and cover if the company starts showing >22-23% growth or meaningful NRR improvement.
• Relative value: long GTLB / short TEAM for a 1-3 month spread trade on enterprise seat expansion. GTLB offers the cheaper multiple and more direct leverage to widening seat count; the pair should work if investors continue rewarding measured growth with valuation discipline.
• Event-driven alert: buy GTLB only on a post-rally pullback if you believe non-developer seats can become a recurring ARR driver over the next 2-3 quarters. If the next update shows the feature set adding accounts rather than just seats, upside can extend 10-15% from entry.
• Risk hedge: if long software beta broadly, use IGV as the hedge rather than single-name protection; GTLB-specific upside is modest, but a sector multiple de-rate from higher yields would hit names with no acceleration first.